Virginia Litwin

Biography

Virginia Litwin joined Caprion in September 2017 as the Vice President of Immunology. She is an internationally recognized thought-leader in bringing “Cytometry from Bench-to-Bedside” through the implementation of state-of-the-art and robust processes. Virginia co-founded the Flow Cytometry Action Program Committee (APC) within the American Association of Pharmaceutical Scientists (AAPS) and is a councilor for both the International Society for the Advancement of Cytometry (ISAC) and the International Clinical Cytometry Society (ICCS). In addition, she serves on the ICCS Advocacy Committee whose mission is to interface with regulatory agencies. She is also the chair of the Document Development Committee for a new Clinical Laboratory Standards Institute Guideline, H62- the Validation of Assays Performed by Flow Cytometry. Virginia co-edited the book, Flow Cytometry in Drug Discovery and Development and a special issue of the Journal of Immunology Methods on Flow Cytometry Biomarkers and Translational Medicine and recently she was a guest editor for a special issue of Cytometry Part B: Clinical Cytometry, focusing on receptor occupancy. In 2013, she was invited to present at the FDA workshop on clinical flow cytometry following the publication of one of the first papers on flow cytometry method and instrument validation. She will also be presenting at the upcoming NIST-FDA Flow Cytometry Workshop: Building Measurement Assurance in Flow Cytometry. Virginia received a Ph.D. in Virology/Immunology from the University of Iowa and joined Lewis Lanier at DNAX as a post-doctoral fellow where she identified one of the first human KIR receptors. Later, at Progenics Pharmaceuticals, she was part of the team which characterized the role of CC-CKR5 in HIV viral entry. Prior to joining the Company, Virginia was the Senior Principal Scientist and global scientific leader for flow cytometry at Covance. Virginia Litwin joined Caprion in September 2017 as the Vice President of Immunology. She is an internationally recognized thought-leader in bringing “Cytometry from Bench-to-Bedside” through the implementation of state-of-the-art and robust processes. Virginia co-founded the Flow Cytometry Action Program Committee (APC) within the American Association of Pharmaceutical Scientists (AAPS) and is a councilor for both the International Society for the Advancement of Cytometry (ISAC) and the International Clinical Cytometry Society (ICCS). In addition, she serves on the ICCS Advocacy Committee whose mission is to interface with regulatory agencies. She is also the chair of the Document Development Committee for a new Clinical Laboratory Standards Institute Guideline, H62- the Validation of Assays Performed by Flow Cytometry. Virginia co-edited the book, Flow Cytometry in Drug Discovery and Development and a special issue of the Journal of Immunology Methods on Flow Cytometry Biomarkers and Translational Medicine and recently she was a guest editor for a special issue of Cytometry Part B: Clinical Cytometry, focusing on receptor occupancy. In 2013, she was invited to present at the FDA workshop on clinical flow cytometry following the publication of one of the first papers on flow cytometry method and instrument validation. She will also be presenting at the upcoming NIST-FDA Flow Cytometry Workshop: Building Measurement Assurance in Flow Cytometry. Virginia received a Ph.D. in Virology/Immunology from the University of Iowa and joined Lewis Lanier at DNAX as a post-doctoral fellow where she identified one of the first human KIR receptors. Later, at Progenics Pharmaceuticals, she was part of the team which characterized the role of CC-CKR5 in HIV viral entry. Prior to joining the Company, Virginia was the Senior Principal Scientist and global scientific leader for flow cytometry at Covance.

Research Interest

Clinical Pharmacy  Pharmaceutical Administration Medicinal Chemistry